RF
+
Aptamer therapeutic illustration
RF
+
Aptamer therapeutic illustration
RF
+
Aptamer therapeutics illustration
RF
+
Aptamer technology illustration
RF
+
Aptamer bound to a protein illustration
RF
+
Structure of an aptamer illustration
RF
+
Structure of an aptamer illustration
RF
+
Structure of an aptamer illustration
RF
+
Structure of an aptamer illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint ventu
RF
+
Structure of an aptamer illustration
RF
+
Structure of an aptamer illustration
RF
+
Xenotransplantation conceptual illustration
RF
+
Heart attack conceptual illustration
RF
+
Heart attack conceptual illustration
RF
+
Kidney pain conceptual illustration
RF
+
Kidney pain conceptual illustration
RF
+
Kidney pain conceptual illustration
RF
+
Kidney pain conceptual illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint ventu
RF
+
Kidney pain conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Large intestine illustration
RF
+
Large intestine illustration
RF
+
Large intestine illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya (L) smiles with executives from Fujitsu Miz
RF
+
Large intestine illustration
RF
+
Large intestine illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
ED
+
November 12 2020 Kawasaki Japan - This picture shows the headquarters of Japanese drug design venture PeptiDream in Kawasaki suburban Tokyo on Thu
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
ED
+
November 12 2020 Kawasaki Japan - This picture shows a logo of Japanese drug design venture PeptiDream at the companys headquarters in Kawasaki s
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Headache conceptual illustration
RF
+
Stomach conceptual illustration
RF
+
Stomach conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration by JULIEN TROMEURSCIENCE PHOTO LIBRARY
RF
+
Prostate cancer conceptual illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint ventu
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration by JULIEN TROMEURSCIENCE PHOTO LIBRARY
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration by JULIEN TROMEURSCIENCE PHOTO LIBRARY
RF
+
Prostate cancer conceptual illustration by JULIEN TROMEURSCIENCE PHOTO LIBRARY
RF
+
Prostate cancer conceptual illustration
RF
+
Prostate cancer conceptual illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint ventu
RF
+
Large intestine illustration
RF
+
Breast cancer conceptual illustration
RF
+
Breast cancer conceptual illustration by JULIEN TROMEURSCIENCE PHOTO LIBRARY
RF
+
Neck pain illustration
RF
+
Neck pain illustration
RF
+
Adalimumab binding tumour necrosis factor-alpha illustration
RF
+
Adalimumab binding tumour necrosis factor-alpha illustration
RF
+
Adalimumab binding tumour necrosis factor-alpha illustration
RF
+
Adalimumab binding tumour necrosis factor-alpha illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint ventu
RF
+
Adalimumab binding tumour necrosis factor-alpha illustration
RF
+
Adalimumab binding tumour necrosis factor-alpha illustration
RF
+
Neck pain conceptual illustration
RF
+
Neck pain conceptual illustration
RF
+
Target cell abnormal red blood cell illustration
RF
+
Human thymic stromal lymphopoietin protein illustration
RF
+
Human thymic stromal lymphopoietin protein illustration
RF
+
Interleukin-31 protein structure illustration
RF
+
Respiratory syncytial virus illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint ventu
RF
+
Respiratory syncytial virus illustration
RF
+
Antibody binding to respiratory syncytial virus illustration
RF
+
Monoclonal antibodies illustration
RF
+
Monoclonal antibody illustration
RF
+
Cyclooxygenase-1 and 2 illustration
RF
+
Cyclooxygenase-1 and 2 illustration
RF
+
Rheumatoid arthritis treatment illustration
RF
+
Rheumatoid arthritis illustration
RF
+
Rheumatoid arthritis illustration
ED
+
November 12 2020 Kawasaki Japan - Japans drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint ventu
1009
0
https://www.afloimages.com/search/drug%20target.html